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ABSTRACT
Purpose Acotiamide, a gastroprokinetic agent used to treat
functional dyspepsia, is transported to at least two compart-
ments in rat stomach. However, the role of these stomach
compartments in pharmacokinetics and pharmacodynamics
of acotiamide remains unclear. Thus, the purpose of this study
was to elucidate the relationship of the blood and stomach
concentration of acotiamide with its inhibitory effect on ace-
tylcholinesterase (AChE).
Methods Concentration profiles of acotiamide and acetyl-
choline (ACh) were determined after intravenous administra-
tion to rats and analyzed by physiologically-based pharmaco-
kinetic and pharmacodynamic (PBPK/PD) model containing
vascular space, precursor pool and deep pool of stomach.
Results Acotiamide was eliminated from the blood and stom-
ach in a biexponential manner. Our PBPK/PD model esti-
mated that acotiamide concentration in the precursor pool
exceeded 2 μM at approximately 2 h after administration.
Acotiamide inhibited AChE activity in vitro with a 50% inhib-
itory concentration of 1.79 μM. ACh reached the maximum
concentration at 2 h after administration.
Conclusions Our PBPK model well described the profile of
acotiamide and ACh concentration in the stomach in the as-
sumption that acotiamide was distributed by carrier mediated
process and inhibited AChE in the precursor pool of stomach.
Thus, Acotiamide in the precursor pool plays an important
role for producing the pharmacological action.
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Functional dyspepsia (FD) is a disease of subjective symptoms,
including postprandial fullness, early satiation, and epigastric
pain, which exhibits no organic abnormalities in the stomach
[1, 2]. Although the pathophysiology of FD is not fully
established, gastric dysmotility has been reported as a putative
cause of FD. Gastric motility is mainly regulated by the cho-
linergic system, which is regulated by factors such as acetyl-
choline (ACh). ACh is released from presynaptic neurons into
the synaptic cleft, where it then binds to ACh receptors and
either affects gastric motility or is inactivated by acetylcholin-
esterase (AChE). This relationship suggests that gastric
motility might be regulated via the inhibition of AChE
activity and that AChE inhibitors might effectively treat
patients with FD [3, 4].
Acotiamide was the first drug to receive approval for use in
treating FD [5–7]. This compound inhibited AChE and en-
hanced the gastric motility like gastric accommodation reflex
and gastric emptying rate after the oral administration of
acotiamide to FD patients [8]. On the other hand some ex-
periments were performed after the subcutaneous administra-
tion of acotiamide to rats to investigate the enhancement of
gastric motility by acotiamide in detail because the exposure
after the subcutaneous administration of acotiamide is higher
than that after the oral administration of acotiamide in rats
[9]. These experiments suggested that acotiamide in the stom-
ach tissue might be effective for enhancement of gastric mo-
tility as the stomach tissue concentration of acotiamide was
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higher than the IC50 for AChE after the subcutaneous admin-
istration of acotiamide to rats [9]. Since the stomach tissue
concentration of acotiamide could be important for the phar-
macological action of acotiamide, the distribution of
acotiamide to the stomach was evaluated in rats [10]. In that
study, acotiamide was highly distributed into the stomach af-
ter the intravenous administration of acotiamide to rats [10].
Moreover, the integration plot analysis indicated that
acotiamide was uptaken by at least two stomach compart-
ments, which rapidly and slowly equilibrated with the blood
[10]. However, as the role of these stomach compartments
were unsettled, the relationship of the blood and stomach
concentration of acotiamide with the pharmacological action
remains unclear.
The purpose of this study was to elucidate the relationship
of the blood and stomach concentration of acotiamide with
the pharmacological action. For the purpose, we developed a
physiologically-based pharmacokinetic and pharmacodynam-
ic (PBPK/PD)model to describe the profiles for concentration
of acotiamide and ACh in rats. In this model, the stomach
compartments rapidly and slowly equilibrated with the blood
were assumed as vascular space and extravascular compart-
ment in rat stomach, respectively. In addition, ACh was cho-
sen as the marker for the pharmacological action of
acotiamide because the reported index like the motility index
might be improper for the describing the time course change
for the pharmacological action of acotiamide. The profiles for
blood and stomach concentration of acotiamide were deter-
mined to characterize the pharmacokinetic parameters.
Moreover, to confirm the elevation of ACh derived from the
inhibition of AChE by acotiamide, the inhibitory effect of






monohydrochloride trihydrate (acotiamide hydrochloride,
Z-338/YM443, Fig. 1) and N-[2-(diisopropylamino)ethyl]-2-[(2,
4,5-trimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide
(ID951551, an internal standard for the determination of
acotiamide) were synthesized in the central research laboratories
of Zeria Pharmaceutical Co., Ltd. (Saitama, Japan). 1,1-Dimeth-
yl-4-acetylthiomethylpiperidinium iodide (MATP+) was pur-
chased from Dojindo Laboratories (Kumamoto, Japan). 5,5′-
Dithiobis-2-nitrobenzoic acid (DTNB), and (±)-sulpiride (an in-
ternal standard for the determination of MATP+−TNB) were
purchased from Sigma-Aldrich Co. LLC (St Louis, MO, USA).
Acetylcholine iodide and N-ethylmaleimide (NEM) were pur-
chased from Wako Pure Chemical Industries (Osaka, Japan).
Acetylcholine-d9 chloride (an internal standard for the determi-
nation of ACh) was purchased from Toronto Research
Chemicals Inc. (Ontario, Canada). All other chemicals were re-
agent grade.
Animals
Male Sprague–Dawley rats (aged 6 to 7 weeks) obtained from
Charles River Japan, Inc. (Kanagawa, Japan) were housed
under standard controlled environmental conditions at 23±
3°C and 55±20% humidity, with a 12-h light/dark cycle
(7:00–19:00, light) and food (CRF-1; Oriental Yeast Co.,
Ltd., Tokyo, Japan) and water available ad libitum. Rats were
allowed to acclimate to laboratory conditions for at least
1 week prior to performing the experiments. All animal ex-
periments were approved by the Animal Care and Use Com-
mittee of the Central Research Laboratories of Zeria Phar-
maceutical Co., Ltd.
Preparation of Stomach Homogenate for In Vitro Study
Rats were anesthetized with isoflurane and their stomachs
immediately excised after blood removal, rinsed with distilled
water, weighed, and homogenized in distilled water to form a
50% (w/v) homogenate. Protein concentrations were deter-
mined using the Bio-Rad protein assay kit (Bio-Rad, Hercules,
CA, USA).
AChE Activity by Stomach Homogenate
AChE activity was measured using MATP+ as a substrate
(50 μM), as previously described [11]. Normally, MATP+ is
hydrolyzed by AChE and reacted with DTNB. The release of
TNB is generally measured with a spectrophotometer at
412 nm to determine AChE activity. However, in the present
study, background absorbance was extremely high in stomach
homogenate (50% [w/v]), which compromised the results.
We therefore measured the concentration of the MATP+
and TNB complex (MATP+−TNB), which was the result of
MATP+ hydrolysis by AChE, using ultra-performance liquid
chromatography (UPLC; Waters, Milford, MA, USA).


















Fig. 1 Structure of acotiamide hydrochloride.
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The reaction medium (0.1 M Na2HPO4 and 0.1 M
NaH2PO4 including 0.5% Triton X-100, pH8.0) contained
10 mM DTNB and 2 mM NEM. Hydrolysis of MATP+ by
AChE was initiated by adding 50 μMMATP+ to an incuba-
tion medium that included the stomach homogenate after
preincubation at 30°C for 3 min. At designated times, 1 ml
of methanol containing 0.1% formic acid was added to termi-
nate the reaction, and an internal standard ([±]-sulpiride) was
then added. Following centrifugation, the supernatant was
evaporated until dry under nitrogen gas in a water bath at
60°C and the residue was dissolved in 200 μl of mobile phase
B (see below for composition). The concentration of MATP+
−TNB in each sample was determined by UPLC using a
hydrophilic interaction chromatography (HILIC) column
(ACQUITY UPLC BEH HILIC; Waters) with MATP+ as
the standard. Ultraviolet absorbance was monitored at
230 nm. Mobile phase A consisted of methanol and 5 mM
ammonium acetate (pH5.0) (50:50). Mobile phase B consisted
of acetonitrile, isopropanol and 5 mM ammonium acetate
(pH5.0) (90:5:5). A steady gradient started at 1%mobile phase
A for 5 min at a flow rate of 1.0 ml/min, moving then to 50%
mobile phase B over the next 4 min, and finally to 1%mobile
phase A from 9 to 12 min.
The initial hydrolysis velocity was calculated using linear
regression of the data taken at 60 s. The effect of acotiamide
on the MATP+ hydrolysis was studied at acotiamide concen-
trations ranging from 0.05 to 25 μM.
In Vivo Study
For the intravenous administration of acotiamide, rats were first
anesthetized with isoflurane. Acotiamide was dissolved in a 5%
glucose solution and then injected to 66 rats in six different ex-
periments via the femoral vein at 1.85 μmol/kg. Blood samples
were collected from the abdominal aorta at 5, 10, 15, and 30min
and 1, 2, 4, 6, 8, 24 and 48 h after drug administration and then
centrifuged to separate the plasma. In addition, at each time
point, the stomach was immediately excised, rinsed with distilled
water, weighed, and homogenized in distilled water to form a
50% (w/v) homogenate. A portion of the homogenate from
5 min to 4 h was set aside for the determination of ACh, and
the remainder was used for the determination of acotiamide
concentration. The concentrations of acotiamide in plasma and
stomach tissue and of ACh in stomach tissue were determined
via liquid chromatography-mass spectrometry (LC-MS/MS) as
described below.
Quantification of Acotiamide by LC-MS/MS
For the quantification of acotiamide, 250 μl of each plasma
sample was mixed with 10 μl of 50% methanol, 250 μl of 2%
trichloroacetate, and an internal standard. The mixtures were
applied to anOasis HLB μElution solid-phase extraction plate
(Waters), and analytes were eluted with 100 μl of methanol.
Distilled water (100 μl) was added to each elute, and 10-μl
aliquots were then subjected to LC-MS/MS.
For the stomach tissue, the stomach homogenate was further
diluted with the same volume of distilled water to the homog-
enate. Thereafter, 10 μl of 50% methanol and 200 μl of 2%
trichloroacetate were added to the solution. Following centrifu-
gation, an internal standard was added to 300 μl of superna-
tant. The solution was applied to an Oasis HLB μElution solid-
phase extraction plate, and the analytes were eluted with 40 μl
methanol. Distilled water (40 μl) was added to each elute, and
20-μl aliquots were then subjected to LC-MS/MS.
LC-MS/MS analysis was performed on an API 4000 tan-
dem mass spectrometer (ABSciex, Foster City, CA, USA)
equipped with a solvent delivery system (LC-30 AD) and
auto-injector (SIL-30 AC; both from Shimadzu, Kyoto,
Japan) using a reverse phase column (CAPCELL PAK C18
MGII; Shiseido, Tokyo, Japan). Electrospray ionization was
performed in the positive-ion mode. Acotiamide and an inter-
nal standard were quantified using the selected reaction-
monitoring mode with a flow rate of 0.8 ml/min methanol/
20 mM ammonium acetate (pH6.0) (6:4). The monitoring
ions for acotiamide and the internal standard were m/z
451→m/z 271 and m/z 465→m/z 364, respectively.
Quantification of ACh by LC-MS/MS
For the quantification of ACh, 20 μl of stomach homogenate
sample was mixed with 100 μl of acetonitrile, and 10 μl of
internal standard was then added to the resulting solution.
After centrifugation for 10 min (16,000×g), the supernatant
was collected and subjected to LC-MS/MS.
LC-MS/MS analysis was performed on an API 4000 tan-
dem mass spectrometer with a solvent delivery system (LC-
30 AD) and auto-injector (SIL-30 AC) using a HILIC column
(Atlantis HILIC; Waters). Electrospray ionization was per-
formed in positive-ion mode. ACh and an internal standard
were quantified using the selected reaction-monitoring mode
at a flow rate of 0.3 ml/min acetonitrile/10 mM ammonium
formate (pH 3.0) (65:35). The monitoring ions for ACh and
the internal standard were m/z 146→m/z 87 and m/z 155→
m/z 87, respectively.
PBPK/PD Model
All plasma concentration data were converted to blood con-
centration data using Eq. 1, as follows:
Ca ¼ Cp⋅Rbp ð1Þ
where Ca, Cp, and Rbp denote the arterial blood concentra-
tion, plasma concentration, and blood-to-plasma concentra-
tion ratio (Rbp=0.84), respectively.
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The blood concentrations of acotiamide were fitted to
Eq. 2, as follows:
C1 ¼ D⋅ α−k2ð ÞV 1⋅ α−βð Þ ⋅e
−α⋅t þ D⋅ k2−βð Þ
V 1⋅ α−βð Þ ⋅e
−β⋅t ð2Þ
The tissue concentrations of acotiamide were analyzed by
the model shown in Fig. 2. The mass balance equations of
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¼ V T ⋅CT ⋅kass−V d ⋅Cd ⋅kass ð5Þ
Vd, Vstomach and Cstomach are defined by the following
equations:
V d ¼ V T ⋅kasskdis ð6Þ
V stomach ¼ V T þ V d ð7Þ
Cstomach ¼ AT þ AdV stomach ð8Þ
where AT and Ad denote the amounts of acotiamide in the
precursor and deep pools, respectively; C1, Ce, CT, and Cd
denote the acotiamide concentrations in the arterial blood,
vascular space, precursor pool, and deep pool, respectively;
and Ve, VT, and Vd denote the volumes of the vascular space,
precursor pool, and deep pool, respectively. Qt and Vstomach
represent blood flow rate and stomach tissue volume, respec-
tively. fb∙PSinf and fu∙PSeff are the permeation clearances for
the influx and efflux of acotiamide between the vascular space
and precursor pool, respectively. The deep pool operates un-
der linear conditions and can be characterized by first-order
rate constants (kass and kdis). Ve can be described as the prod-
uct of Vi and tissue weight [12]. Data fitting of the model
equations was performed using the Phoenix model of the
WinNonlin version 6.1 (Pharsight Corp., Mountain View,
CA, USA).
ACh concentration in the stomach was simulated
using the following model. A pharmacodynamic (PD)
model was used as Model 2 [13, 14], and integrated
into the PBPK model to estimate the stomach distribu-
tion of ACh. According to Model 2, the rate of change
in drug response can be described as follows:
dR
dt
¼ kin−kout⋅ 1− CTIC50 þ CT
 
⋅R ð9Þ
where kin is the zero-order constant for the production
of ACh, and kout defines the first-order rate constant of
Fig. 2 Physiologically-based pharmacokinetic and pharmacodynamic model to describe the distribution of acotiamide and AChE inhibition in rat stomach
following intravenous administration. All terms and mass balance for the model are described in BMaterials and Methods^.
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hydrolysis of ACh by AChE. R is the observed concen-
tration of ACh, and IC50 is the acotiamide concentra-
tion that produces 50% maximal effect. Data fitting of
the model equations was performed using the Phoenix
model of the WinNonlin version 6.1.
RESULTS
PBPK Modeling
Upon modeling of the disposition of acotiamide in rats, the
blood and stomach concentrations of acotiamide were deter-
mined after the intravenous administration of acotiamide to
rats (Fig. 3). The gastric concentration of acotiamide in the
first two sampling point was approximately equal, suggesting
the involvement of the time-consuming process in the distri-
bution of acotiamide into the stomach. The assumption was
supported by the result of integration plot analysis in our pre-
vious report, which showed that the distribution of acotiamide
in the stomach consisted of both rapid and slow equilibrium
with the blood [10]. We therefore assumed that the vascular
space was involved in rapid equilibrium with the blood and
the extravascular compartment was involved in slow equilib-
rium with the blood (Fig. 2). Moreover, the blood-flow inde-
pendent membrane permeability clearance (fb∙PSinf) reported
in our previous report [10], which suggested that carrier
mediated uptake process was involved in the distribution of
acotiamide to the stomach, was applied to the distribution
process of acotiamide into the stomach. After the distribution
process, acotiamide was eliminated from the blood and stom-
ach in a biexponential manner (Fig. 3). Acotiamide in the
stomach was slowly eliminated compared with the blood com-
partment (Fig. 3). We assumed the precursor pool where
acotiamide is unbound and the deep pool where acotiamide
nonspecifically interacts with cellular components (Fig. 2).
Overall, acotiamide is first distributed into the vascular space,
and subsequently transported from the vascular space to the
precursor pool in our PBPK model.
Analysis of Blood and Stomach Concentrations
of Acotiamide
The blood and stomach concentrations were fitted to a PBPK
model describing the time course of acotiamide concentration
in the blood and stomach (Fig. 3). The concentration of
acotiamide in the precursor pool of stomach decreased to
approximately 2 μM at 2 h after administration. The concen-
tration of acotiamide in the deep pool of stomach was estimat-
ed below 0.01 μMafter the administration of acotiamide. The
terminal phase for the stomach concentration was well fitted
by the deep pool of stomach. The kinetic parameters for
acotiamide are summarized in Table I. The fitting quality or
suitability of the PBPK model was assessed using the maxi-
mized log-likelihood function (Loglik) and Akaike’s informa-
tion criterion (AIC), which indicated that the developed PBPK
model is appropriate for describing the kinetics of acotiamide
(Fig. 3 and Table II).
Inhibition of the Hydrolysis of MATP+ by Acotiamide
The effect of acotiamide on AChE derived from rat stomach is
shown in Fig. 4. The hydrolysis velocity of MATP+ decreased
with increasing acotiamide concentration, with an IC50 value
of 1.79 μM (Table I).
PD Modeling
The indirect response model was linked with the PBPKmodel
for describing the inhibition of AChE by acotiamide. The
concentration of acotiamide used in the PDmodel was chosen
as the concentration of acotiamide in the precursor pool of
stomach, which covered the IC50 value for the inhibition of
AChE by acotiamide.
Analysis of Stomach Concentration of ACh
The profile of ACh after the administration of acotiamide is
shown in Fig. 5. The concentration of ACh rose to 131% (%
of baseline) at 2 h after administration of acotiamide. When
Fig. 3 Profiles and model simulations of acotiamide concentrations in the
blood, stomach, precursor pool, and deep pool after intravenous administra-
tion to rats. Each point and vertical bar represents the mean±S.E. of six rats.
All values of S.E. are inside the symbols. Open and closed circles indicate
blood concentration and stomach concentration, respectively. Solid, dotted,
dashed, and dashed-dotted lines represent the time course of acotiamide
concentration in the blood, stomach, precursor pool, and deep pool, respec-
tively. Symbols represent experimentally observed concentrations; lines are
simulated concentration profiles using the PBPK model from Fig. 2.
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the data of ACh concentrations was fitted to our PBPK/PD
model without fixing the PD parameters (kin, kout and IC50),
kin, kout and IC50 were 0.00337 nmol/g of tissue/min,
0.00446 min−1 and 2.10 μM, respectively. At that fitting,
Loglik and AIC were 43.9 and −75.8, respectively, which
indicated that the PBPK/PD model is appropriate for de-
scribing the kinetics of ACh. When the data of ACh concen-
trations was fitted to our model with fixing IC50 (1.79 μM), the
profile of stomach concentration of ACh was well estimated
by the PBPK/PDmodel on the assumption that acotiamide in
the precursor pool of stomach inhibited AChE (Fig. 5).
DISCUSSION
The stomach concentration of acotiamide was higher than the
blood concentration in the first time point when acotiamide
concentration was measured after intravenous administration
of acotiamide to rats. Acotiamide was slowly eliminated in the
stomach compared to the blood. Our PBPK model well de-
scribed the profile of acotiamide concentration in the blood
and stomach in the assumption that acotiamide was rapidly
distributed into the vascular space, uptaken to the precursor
pool of stomach by carriermediated process and permeated in
the deep pool of stomach. ACh, which was determined as the
marker of the involvement of acotiamide in inhibiting AChE,
reached the maximum concentration in the stomach at 2 h
after intravenous administration of acotiamide, while the
stomach concentration of acotiamide peaked at 0.0833 h, in-
dicating the existence of time lag between the stomach con-
centration of acotiamide and ACh. The unbound concentra-
tion of acotiamide in the precursor pool was higher than the
in vitro IC50 value of acotiamide for inhibiting AChE activity
by approximately 2 h after administration of acotiamide. The
PD model well described the profile of ACh concentration in
the stomach in the assumption that the unbound concentra-
tion of acotiamide in the precursor pool inhibited AChE with
Table I Physiological and Pharma-
cokinetic Parameters for PBPK
Analysis in Rats
Parameter Value Source
V1 (ml/kg) 302 By fitting
k1 (min
−1) 0.126 By fitting
k2 (min
−1) 0.0313 By fitting
CLtot (ml/min/kg) 56.9 By fitting
Ve (ml) 0.441 Calculated from Vi [10] and tissue weight [12]
Vstomach (ml) 1.1 Hosseini-Yeganeh and McLachlan [12]
fb·PSinf (ml/min) 0.174 Yoshii et al., 2011 [10]
Qt (ml/min) 1.1 Hosseini-Yeganeh and McLachlan [12]
VT (ml) 0.133 By fitting
fu·PSeff (ml/min) 0.00600 By fitting
kass (min
−1) 0.0000320 By fitting
kdis (min
−1) 0.00000485 By fitting
IC50 (μM) 1.79 In vitro study
kin (nmol/g of tissue/min) 0.00314 By fitting
kout (min
−1) 0.00415 By fitting
Table II Fitting Quality of
the PBPK Model for the
Time Course of
Acotiamide Concentra-




Loglik, maximized log-likelihood function;
AIC Akaike’s information criterion
Calculated using number of observations=
26 and number of parameters=5
Fig. 4 Inhibition of MATP+ hydrolysis by acotiamide. Each point and vertical
bar showing the hydrolysis velocity (v0) of MATP+ represents the mean±S.E.
for three determinations.
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the in vitro IC50 for AChE inhibition. These results suggested
that acotiamide inhibited AChE in the precursor pool of stom-
ach where acotiamide was distributed by carrier mediated
process.
To our knowledge, no reports have been published on a
PKmodel for the distribution of drugs from blood to stomach
as the pharmacological target although some reports have
been reported on a PK model containing stomach as delivery
organ of drugs to small intestine [15–17]. The precursor and
deep pool of stomach were put in our model to describe the
rate-limiting step in the uptake of acotiamide by stomach and
slower elimination of acotiamide from stomach than blood.
Acotiamide in the precursor pool of stomach plays an impor-
tant role in the elevation of ACh in the stomach though the
anatomical meanings of these compartments remain unclear.
It’s normally difficult to estimate the microenvironmental con-
centration of drugs in tissue. For brain, microdialysis method
was applied to estimate the unbound concentration of drugs
penetrating into brain [18, 19]. The method for prediction of
the unbound concentration of drugs in brain was also report-
ed by Fridén et al. [20]. For stomach, the application of mi-
crodialysis to submucosa which is thicker than muscular layer
and unrelated with gastric motility in the gastric layers was
only reported [21, 22]. Moreover, there is no report
concerning the method for prediction of the unbound concen-
tration of drugs in stomach. Thus, we proposed a mechanism
based PK model to estimate the concentration of drugs
exerting their pharmacological effects in tissues like
gastroprokinetic agents in stomach.
The selectivity of drug to its target is achieved by the spe-
cific affinity to drug targets, the selective access to site where
drug targets exist, and/or the unique localization of drug tar-
get. For example, histamine H2 receptor, which is only in-
volved in the regulation of gastric acid secretion among four
subtypes of histamine H receptor, is a selective target for the
suppressor of gastric acid secretion [23, 24]. L-type amino
acid transporter 1 is consider as a specific target for antitumor
because L-type amino acid transporter 1, transporting amino
acids needed for the growth of cancer cells, selectively ex-
presses in cancer cells [25, 26]. AChE, the target of acotiamide
is a ubiquitous enzyme. In addition, ACh which is regulated
by AChE interacts with each subtype of muscarinic receptor.
There might be no selectivity on the pathway from the contact
of acotiamide with AChE to the evoking of pharmacological
action, so the selectivity of acotiamide to its target might be
derived only from the feature in the distribution of
acotiamide. Thus, it’s seems important to put in the distribu-
tion parameters to stomach in the development of our PBPK/
PD model. fb∙PSinf of the distribution parameters was calcu-
lated from the uptake clearance of acotiamide to stomach
[10]. The uptake clearance can be expressed as the slope in
the integration plot, where stomach to blood concentration
ratio is plotted against area under the blood concentration
curve to blood concentration ratio when the uptake of
acotiamide was determined in a short time, during which
the efflux and/or elimination of acotiamide from stomach
were negligible. Ve of the distribution parameters (0.401 ml/
g of tissue) was calculated as the product of the intercept (Vi) of
y axis of integration plot and tissue weight (Vi ∙ tissue weight).
When Ve was compared with the volume of capillary bed
(0.0108 ml/g of tissue) [27] and inulin space (0.295 ml/g of
tissue) [10], Ve was similar to inulin space, an extracellular
space. Therefore, fb∙PSinf might represent the transport of
acotiamide through plasma membrane of gastric cells. More-
over, the volume of precursor pool (VT) which was 12.1% of
the volume of stomach (Vstomach) was similar to fraction of
acotiamide distributed to the stomach cytosol (12.0%) report-
ed in our previous report [10]. The result suggested that the
volume of precursor and deep pool reflected fraction of
acotiamide distributed to cytosol and organelle of gastric cells,
respectively.
The time lag between drug concentration and the effect
was often observed [13, 14, 28]. For describing the delay of
drug effect, the PD models like hypothetical effect compart-
ment model and indirect response model were used. The hy-
pothetical effect compartment model is useful in the case that
mechanism of the delay for drug effect is unknown, while the
indirect response model is available for drugs whose mecha-
nism of the delay is derived from the mechanism of action. An
indirect response model was chosen as our PD model because
acotiamide is a known AChE inhibitor. Dayneka et al. classi-
fied the indirect response model into four models types-based
on the mechanism of action [13]. Based on this classification,
the effects of reversible anticholinesterase agents, which inhibit
Fig. 5 Profile and model simulation of ACh concentration in the stomach
homogenate after intravenous administration of acotiamide to rats. Each point
and vertical bar represents the mean±S.E. of six rats. Symbols represent
experimentally observed concentrations, while curves show the simulated
concentration profiles from the PBPK/PD model (Fig. 2).
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the enzymatic breakdown of ACh, demonstrated that our
model could be categorized as Model 2. The rate of change
in drug response using this model is described by Eq. 9, and
many drugs described in this manner show a delay compared
to the time course of the drug concentration. Jusko et al. used
an indirect response model to describe the muscular response
as ACh level in patients withmyasthenia gravis during therapy
using pyridostigmine, acetylcholinesterase inhibitor [29].
Therefore, the indirect response model is suitable for describ-
ing the inhibitory effect of acotiamide on AChE in rat
stomach.
Normally, acetylthiocholine (ATCh) is used to evaluate
AChE activity [30]. However, ATCh is a known substrate of
both AChE and butyrylcholinesterase (BChE), meaning
BChE inhibitors such as iso-OMPA need to be included in
the incubation medium when investigating acotiamide effects
[31]. Recently, Kikuchi et al. reported that MATP+ was suit-
able AChE selective substrates for detecting of AChE activity
[11]. Therefore, in this study, we usedMATP+ as substrate of
AChE for investigation of the effects of acotiamide on the
AChE activity. Hydrolysis velocity of MATP+ was decreased
by the addition of acotiamide, with the IC50 value of 1.79 μM.
Kawachi et al. have reported that acotiamide inhibited ATCh
hydrolysis by stomach homogenate with IC50 value of 2.3 μM
[9]. Furthermore, acotiamide also inhibited human AChE
with Ki value of 0.61 μM [31]. Our observation was similar
to these previously results, therefore, it was considered that
using of MATP+ for investigation of AChE inhibition is
appropriate.
In conclusion, we elucidated the relationship of the blood
and stomach concentration of acotiamide with the pharmaco-
logical action. Acotiamide was distributed by carrier mediated
process and inhibited AChE in the precursor pool of stomach.
Acotiamide in the precursor pool plays an important role for
producing the pharmacologic action. Moreover, we proposed
PBPK/PD model to describe the pharmacologic action of
acotiamide in stomach.
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